Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle ® (follitropin delta); alongside its existing unique algorithm-based dosing
Article content
PARIS — Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications. 1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved.
Article content
Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established 4,5,6,7,8, particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle. 4,5,6,7,8 Key Findings:
Ovarian Response: Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy
Clinical Pregnancy Rates: Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa
Drug Product Usage: After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU)
OHSS Rates: Early OHSS rates were low (2.5% for follitropin delta and 3.0% for follitropin alfa), with no cycle cancellations due to excessive ovarian response on either arm of the study.
Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: 'No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta.'
Article content
Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: 'The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities.'
Article content
About GnRH protocols
Article content
Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI. 7,8 About Follitropin Delta (Rekovelle ®) Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response. 3 It is the first rFSH derived from a human cell line (PER.C6 ® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins. 3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman's AMH level and body weight. 3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. 5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio. 3 About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.
Article content
REFERENCES
Article content
1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020
Article content
2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022
Article content
3 – Clinical Trials.gov page: https://clinicaltrials.gov/study/NCT05263388 (Accessed June 2025)
Article content
4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396.
Article content
5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482.
Article content
6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17.
Article content
7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29.
Article content
8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
For more information, please contact
Article content
M
Article content
atthew Worrall
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
A couple tried for 18 years to get pregnant. AI made it happen
After trying to conceive for 18 years, one couple is now pregnant with their first child thanks to the power of artificial intelligence. The couple had undergone several rounds of in vitro fertilization, or IVF, visiting fertility centers around the world in the hopes of having a baby. The IVF process involves removing a woman's egg and combining it with sperm in a laboratory to create an embryo, which is then implanted in the womb. But for this couple, the IVF attempts were unsuccessful due to azoospermia, a rare condition in which no measurable sperm are present in the male partner's semen, which can lead to male infertility. A typical semen sample contains hundreds of millions of sperm, but men with azoospermia have such low counts that no sperm cells can be found, even after hours of meticulous searching under a microscope. So the couple, who wish to remain anonymous to protect their privacy, went to the Columbia University Fertility Center to try a novel approach. It's called the STAR method, and it uses AI to help identify and recover hidden sperm in men who once thought they had no sperm at all. All the husband had to do was leave a semen sample with the medical team. 'We kept our hopes to a minimum after so many disappointments,' the wife said in an emailed statement. Researchers at the fertility center analyzed the semen sample with the AI system. Three hidden sperm were found, recovered and used to fertilize the wife's eggs via IVF, and she became the first successful pregnancy enabled by the STAR method. The baby is due in December. 'It took me two days to believe I was actually pregnant,' she said. 'I still wake up in the morning and can't believe if this is true or not. I still don't believe I am pregnant until I see the scans.' Artificial intelligence has advanced the field of fertility care in the United States: More medical facilities are using AI to help assess egg quality or screen for healthy embryos when patients are undergoing IVF. There's still more research and testing needed, but AI may now be making advancements in male infertility, in particular. Dr. Zev Williams, director of the Columbia University Fertility Center, and his colleagues spent five years developing the STAR method to help detect and recover sperm in semen samples from people who had azoospermia. They were struck by the system's results. 'A patient provided a sample, and highly skilled technicians looked for two days through that sample to try to find sperm. They didn't find any. We brought it to the AI-based STAR System. In one hour, it found 44 sperm. So right then, we realized, 'Wow, this is really a game-changer. This is going to make such a big difference for patients,' ' said Williams, who led the research team. When a semen sample is placed on a specially designed chip under a microscope, the STAR system – which stands for Sperm Tracking and Recovery – connects to the microscope through a high-speed camera and high-powered imaging technology to scan the sample, taking more than 8 million images in under an hour to find what it has been trained to identify as a sperm cell. The system instantly isolates that sperm cell into a tiny droplet of media, allowing embryologists to recover cells that they may never have been able to find or identify with their own eyes. 'It's like searching for a needle scattered across a thousand haystacks, completing the search in under an hour and doing it so gently, without any harmful lasers or stains, that the sperm can still be used to fertilize an egg,' Williams said. 'What's remarkable is that instead of the usual [200 million] to 300 million sperm in a typical sample, these patients may have just two or three. Not 2 [million] or 3 million, literally two or three,' he said. 'But with the precision of the STAR system and the expertise of our embryologists, even those few can be used to successfully fertilize an egg.' 'Shocking and unexpected diagnosis' It's estimated that the male partner accounts for up to 40% of all infertility cases in the United States, and up to 10% of men with infertility are azoospermic. 'This often is a really heartbreaking and shocking and unexpected diagnosis,' Williams said. 'Most men who have azoospermia feel completely healthy and normal. There's no impairment of their sexual function, and the semen looks normal, too. The difference is that when you look at it under a microscope, instead of seeing literally hundreds of millions of sperm swimming, you just see cell debris and fragments but no sperm.' Treatment options for azoospermia traditionally have included uncomfortable surgery to retrieve sperm directly from a patient's testes. 'A part of the testes gets removed and broken into little pieces, and you try to find sperm there,' Williams said. 'It's invasive. You can only do it a couple of times before there could be permanent scarring and damage to the testes, and it's painful.' Other treatment options may include prescription hormone medications – but that will be effective only if the person has an imbalance of hormones. If no other treatment options are successful, couples may use donor sperm to have a child. Williams said the STAR method can be a new option. 'It really was a team effort to develop this, and that's what really drove and motivated everybody, the fact that you can now help couples who otherwise couldn't have that opportunity,' he said. Although the method is currently available only at the Columbia University Fertility Center, Williams and his colleagues want to publish their work and share it with other fertility centers. Using the STAR method to find, isolate and freeze sperm for a patient would cost a little under $3,000 total, he said. 'Infertility is unique in a way in that it's such an ancient part of the human experience. It's literally biblical. It's something we've had to contend with through all of human history,' he said. 'It's amazing to think that the most advanced technologies that we currently have are being used to solve this really ancient problem.' 'AI is helping us see what our eyes can't' It's not the first time doctors have turned to AI to help men with azoospermia. A separate research team in Canada built an AI model that could automate and accelerate the process of searching for rare sperm in samples from men with the condition. 'The reason AI is so well-suited for this is AI really relies on learning – showing it an image of what a sperm looks like, what the shape is, what characteristics it should have – and then being able to use that learning algorithm to help identify that specific image that you're looking for,' said Dr. Sevann Helo, a urologist at Mayo Clinic with specialty interest in male infertility and male sexual dysfunction, who was not involved in the STAR method or the research in Canada. 'It's very exciting,' she said. 'AI, in general, at least in the medical community, I think is a whole new landscape and really will revolutionize the way we look at a lot of problems in medicine.' The STAR method is a novel approach to identifying sperm, but AI has been used in many other ways within fertility medicine too, said Dr. Aimee Eyvazzadeh, a San Francisco-based reproductive endocrinologist and host of the podcast 'The Egg Whisperer Show.' 'AI is helping us see what our eyes can't,' Eyvazzadeh, who was not involved in the development of STAR, wrote in an email. For instance, AI algorithms, such as one called Stork-A, have been used to analyze early-stage embryos and predict with 'surprising accuracy' which ones are likely to be healthy. Another AI tool, CHLOE, can assess the quality of a woman's eggs before she may freeze them for future use. 'AI is being used to personalize IVF medication protocols, making cycles more efficient and less of a guessing game. It's also helping with sperm selection, identifying the healthiest sperm even in difficult samples. And AI can now even predict IVF success rates with more precision than ever before, using massive data sets to give patients personalized guidance,' Eyvazzadeh said. 'The common thread? Better decisions, more confidence, and a more compassionate experience for patients.' The new STAR system is 'a game-changer,' she said. 'AI isn't creating sperm – it's helping us find the rare, viable ones that are already there but nearly invisible,' she said. 'It's a breakthrough not because it replaces human expertise, but because it amplifies it – and that's the future of fertility care.' But there is also a growing concern that the rushed application of AI in reproductive medicine could give false hope to patients, said Dr. Gianpiero Palermo, professor of embryology and director of andrology and assisted fertilization at Weill Cornell Medicine. 'AI is gaining a lot of traction nowadays to offer unbiased evaluation on embryos by looking at embryo morphology,' Palermo said in an email. 'However, current available models are still somewhat inconsistent and require additional validation.' Palermo said the STAR approach needs to be validated and would still require human embryologists to pick up sperm and inject them into an egg to create an embryo for patients undergoing IVF. 'Maybe the AI addition may help to retrieve the spermatozoon a little faster and maybe one more than the embryologist,' said Palermo, who was not involved in the development of STAR but was the first to describe the method of injecting sperm directly into an egg. Since he pioneered that method, it has become the most-utilized assisted reproductive technology in the world. 'In my opinion, this approach is faulty because inevitably some men will have no spermatozoa,' Palermo said of the STAR method, 'doesn't matter how their specimens are screened whether by humans or a machine.'
National Post
15 hours ago
- National Post
H2SITE Secures EIC Accelerator Funding to Deploy a Flagship 1 TPD Ammonia Cracker Using Membrane Reactor Technology at a Port in North-West Europe
Article content BILBAO, Spain — H2SITE has been awarded the EIC (European Innovation Council) Accelerator program for a project aimed at deploying a first-of-its-kind ammonia cracking unit capable of producing 1 ton of high-purity hydrogen per day. The system is based on H2SITE's proprietary palladium-based membrane reactor technology, which enables the simultaneous catalytic decomposition of ammonia and selective hydrogen separation within a single unit. Article content This breakthrough technology offers several compelling advantages over conventional ammonia cracking processes: Article content Lowest Levelized Cost of Hydrogen (LCOH) from ammonia due to high efficiency and integrated operation Reduced energy consumption, operating at significantly lower temperatures (400–450 °C) than traditional cracking methods (typically 600–800 °C) High-purity hydrogen output, compliant with ISO 14687 Grade D, suitable for direct use in fuel cells and industrial applications Compact and modular design, facilitating decentralized hydrogen production close to demand centers Article content The ammonia cracking system will serve as a demonstration plant, aiming to validate the commercial and operational readiness of H2SITE's integrated membrane reactor approach at an industrially relevant scale, with the goal of advancing the decarbonization of hard-to-abate sectors. Article content 'This project represents an important milestone for the development of our technology. It enables the next steps toward commercializing our units for industrial sectors, energy hubs (such as ports and large-scale distribution centers), and onboard maritime applications,' Article content said Andres Galnares, CEO of H2SITE. Article content As the hydrogen economy develops, efficient solutions for transporting low-carbon hydrogen are essential. Ammonia is a promising hydrogen carrier due to its high volumetric energy density and existing infrastructure, and more than 20 million tons of ammonia are transported by ship every year. Advances in ammonia cracking technology such as H2SITE's integrated membrane reactor will be an enabler to making this pathway competitive, enabling large-scale, flexible hydrogen supply chains. Article content H2SITE, founded in 2020, is a technology company specializing in the on-site production and separation of high-purity hydrogen. The company utilizes exclusive palladium-alloy membrane reactor technology to efficiently convert various feedstocks including ammonia, methanol, and syngas into hydrogen. Additionally, H2SITE enables the separation of hydrogen from low-concentration gaseous mixtures for applications such as salt caverns or geologic hydrogen. By decentralizing hydrogen production through innovative ammonia cracking and separation solutions, H2SITE addresses the challenges of cost-effective hydrogen transportation and storage, significantly reducing associated costs and emissions. Article content Article content Article content
National Post
a day ago
- National Post
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
Article content Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle ® (follitropin delta); alongside its existing unique algorithm-based dosing Article content PARIS — Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications. 1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved. Article content Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established 4,5,6,7,8, particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle. 4,5,6,7,8 Key Findings: Ovarian Response: Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy Clinical Pregnancy Rates: Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa Drug Product Usage: After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU) OHSS Rates: Early OHSS rates were low (2.5% for follitropin delta and 3.0% for follitropin alfa), with no cycle cancellations due to excessive ovarian response on either arm of the study. Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: 'No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta.' Article content Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: 'The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities.' Article content About GnRH protocols Article content Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI. 7,8 About Follitropin Delta (Rekovelle ®) Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response. 3 It is the first rFSH derived from a human cell line (PER.C6 ® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins. 3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman's AMH level and body weight. 3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. 5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio. 3 About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Article content REFERENCES Article content 1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020 Article content 2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022 Article content 3 – Clinical page: (Accessed June 2025) Article content 4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396. Article content 5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482. Article content 6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17. Article content 7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29. Article content 8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578. Article content Article content Article content Article content Article content Contacts Article content For more information, please contact Article content M Article content atthew Worrall Article content Article content Article content Article content
